New aspects of the mechanisms of development and treatment of irritable bowel syndrome

2013 ◽  
Vol 4 (3) ◽  
pp. 29-35
Author(s):  
Mariya Yuryevna Tipikina ◽  
Yelena Aleksandrovna Korniyenko
Keyword(s):  
Irritable Bowel Syndrome ◽  
Combination Therapy ◽  
Bacterial Overgrowth ◽  
Control Group ◽  
Complex Evaluation ◽  
Before And After ◽  
Irritable Bowel ◽  
Mechanisms Of Development ◽  
And Coping ◽  
Feces Analysis

In 121 children with irritable bowel syndrome (IBS) a complex evaluation of the values of volum threshold sensitivity (VTS) of the rectum, intestinal microbiota according to the findings of feces analysis and lactulose hydrogen test, and also of the activation of inflammation according to endoscopy, histology, stool calprotectin testing and proinflammatory cytokines in the colonic mucosa was performed. The estimation of these parameters before and after treatment with probiotics, trimebutin, combination therapy of pro-and prebiotics, combination therapy trimebutin and probiotics for 1 month. The control group were children receiving placebo. In all patients with IBS enhanced VTS was noted. Signs of inflammation were detected according to the findings of endoscopy in 66.9 %, of histology – in 97.5 %, enhanced levels of calprotectin were found in 27.3 %, enhanced levels of IL-8 — 45 at %, INF-γ — 90 %. In all patients with IBS have disbiotic disorders of the colon, sings of bacterial overgrowth syndrome were detected in 85.1 % of children. Probiotics effective in reducing the VTS, improving of clinical data,microbiological indices, and coping with of inflammatory disorders in the intestines. Are the most effective of treatment with both trimebutin and probiotics, or probiotics and prebiotic lasting at least one month.

Bifidobacterium infantis M-63 improves mental health in victims with irritable bowel syndrome developed after a major flood disaster

2019 ◽  
Vol 10 (2) ◽  
pp. 111-120 ◽  
Author(s):  
Z.F. Ma ◽  
N. Yusof ◽  
N. Hamid ◽  
R.M. Lawenko ◽  
W.M.Z. Wan Mohammad ◽  
...  
Keyword(s):  
Mental Health ◽  
Irritable Bowel Syndrome ◽  
Bodily Pain ◽  
Depression Scale ◽  
Bacterial Overgrowth ◽  
Well Being ◽  
Bifidobacterium Infantis ◽  
Before And After ◽  
Irritable Bowel ◽  
Lower Ratio

Individuals in a community who developed irritable bowel syndrome (IBS) after major floods have significant mental health impairment. We aimed to determine if Bifidobacterium infantis M-63 was effective in improving symptoms, psychology and quality of life measures in flood-affected individuals with IBS and if the improvement was mediated by gut microbiota changes. Design was non-randomised, open-label, controlled before-and-after. Of 53 participants, 20 with IBS were given B. infantis M-63 (1×109 cfu/sachet/day) for three months and 33 were controls. IBS symptom severity scale, hospital anxiety and depression scale, SF-36 Questionnaire, hydrogen breath testing for small intestinal bacterial overgrowth and stools for 16S rRNA metagenomic analysis were performed before and after intervention. 11 of 20 who were given probiotics (M-63) and 20 of 33 controls completed study as per-protocol. Mental well-being was improved with M-63 vs controls for full analysis (P=0.03) and per-protocol (P=0.01) populations. Within-group differences were observed for anxiety and bodily pain (both P=0.04) in the M-63 per-protocol population. Lower ratio of Firmicutes/Bacteroidetes was observed with M-63 vs controls (P=0.01) and the lower ratio was correlated with higher post-intervention mental score (P=0.04). B. infantis M-63 is probably effective in improving mental health of victims who developed IBS after floods and this is maybe due to restoration of microbial balance and the gut-brain axis. However, our conclusion must be interpreted within the context of limited sample size. The study was retrospectively registered on 12 October 2017 and the Trial Registration Number (TRN) was NCT03318614.

scholarly journals Comparison of Laughter Yoga and Anti-Anxiety Medication on Anxiety and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome

2019 ◽  
Vol 11 (4) ◽  
pp. 211-217 ◽  
Author(s):  
Tahmine Tavakoli ◽  
Navid Davoodi ◽  
Toktam Sadat Jafar Tabatabaee ◽  
Zeinab Rostami ◽  
Homa Mollaei ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Symptoms ◽  
Symptomatic Treatment ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Yoga Group ◽  
Gi Symptoms ◽  
Before And After ◽  
The Difference ◽  
Irritable Bowel

BACKGROUND Irritable bowel syndrome (IBS) is the most common chronic gastrointestinal (GI) disorder. Patients with IBS usually suffer from anxiety and depression. A combination of psychological approaches and pharmacological treatments can be a significantly effective treatment for IBS. The main objective of the present study was to provide a therapeutic plan based on laughter yoga and anti-anxiety medication, employed for the very first time, and to determine the effectiveness of these treatments on the anxiety and GI symptoms of patients with IBS. METHODS In this randomized, controlled, clinical trial, the participants were 60 patients selected from those who referred to the GI clinic of Vali-asr Hospital (Birjand, Iran) during the study period (April 2017 to March 2017) and were diagnosed as having IBS based on ROME III criteria. The participants were randomly assigned to either the laughter yoga group, the anti-anxiety medication group, or the symptomatic treatment (control) group. Severity levels of anxiety and GI symptoms before and after intervention were determined and compared among these three groups according to approved protocols. RESULTS The severity of IBS symptoms after the interventions was more greatly reduced in the laughter yoga group than in the anti-anxiety medication and control groups (p = 0.006). The severity of anxiety after interventions decreased in all three groups, especially in the yoga treatment group, but the difference was not statistically significant (p = 0.1). CONCLUSION Laughter yoga is more effective than anti-anxiety medication in reducing the GI symptoms of patients with IBS. Therefore, applying laughter yoga along with common pharmacological therapies for patients with IBS might be strongly advised.

scholarly journals Therapeutic Analysis of Fuzi Lizhong Wan with Trimebutine in the Treatment of Diarrhea Type Irritable Bowel Syndrome

2020 ◽  
Vol 4 (4) ◽  
Author(s):  
Ying Chang ◽  
Quanwei Di ◽  
Gaixian Di
Keyword(s):  
Irritable Bowel Syndrome ◽  
Treatment Group ◽  
Clinical Efficacy ◽  
Combined Therapy ◽  
Control Group ◽  
Symptom Scores ◽  
Before And After ◽  
Random Number Table ◽  
Irritable Bowel

Objective: To evaluate the clinical efficacy of Fuzi Lizhong Wan and trimebutine in the treatment of diarrhea irritable bowel syndrome. Methods: A total of 90 patients with diarrhea irritable bowel syndrome were divided into control group  (n=45) and treatment group (n=45) using the random number table method. Patients in the control group were po administered with trimebutine 0.2 g, three time daily for 4 weeks. Patients in the treatment group were po administered with Fuzi Lizhong Wan 9 g, three time daily for 4 weeks on the basis of the control group. The clinical efficacy and the TCM symptom scores were evaluated after treatment. The serological indicators in two groups were compared before and after treatment. Results: After treatment, the clinical efficacy and the TCM symptom scores in treatment group were significantly lower than that in control group(P<0.05).The levels of serological indicators in both groups improved significantly, and those in the treatment group were better than the control group(P<0.05). Conclusion: Combined therapy of Fuzi Lizhong Wan and trimebutine in the treatment of diarrhea type irritable bowel syndrome has a significant effect, which can relieve clinical symptom, and reduce visceral sensitivity, and improve levels of inflammatory and quality of life. So it is suggested to be applied.

scholarly journals Effects of Alkaline-Reduced Drinking Water on Irritable Bowel Syndrome with Diarrhea: A Randomized Double-Blind, Placebo-Controlled Pilot Study

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Dong Woo Shin ◽  
Hyuk Yoon ◽  
Hyun Soo Kim ◽  
Yoon Jin Choi ◽  
Cheol Min Shin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Control Group ◽  
Double Blind ◽  
Significant Group ◽  
Before And After ◽  
Irritable Bowel ◽  
Reduced Drinking

Objectives. The purpose of this study was to investigate whether the ingestion of alkaline-reduced water (ARW) is helpful in improving the symptoms of diarrhea-predominant irritable bowel syndrome (IBS). Methods. Twenty-seven patients (male, 25.9%; mean, 41.7 years old) with diarrhea-predominant IBS were randomly allocated to two groups. For eight weeks, the ARW group (n=13) ingested at least 2 liters/day of ARW, while the control group (n=14) ingested placebo water. IBS symptom scores (quality-of-life, abdominal pain/discomfort), stool form, and frequency were assessed before and after treatment via questionnaires. Results. Eight patients (61.5%) in the ARW group and six patients (42.9%) in the control group indicated that their symptoms had improved in more than four out of the eight weeks of treatment (p=0.449). The IBS quality-of-life score significantly improved from 57.2 to 30.8 in the ARW group; this improvement was significantly greater than the slight improvement from 48.7 to 42.2 observed in the control group (p=0.029). The abdominal pain score improved from 1.8 to 0.9 in the ARW group and from 1.8 to 1.1 in the control group, with no significant group difference (p=0.232). Conclusions. Drinking ARW for eight weeks improves the quality of life in patients with diarrhea-predominant IBS.

scholarly journals The Effectiveness of Acceptance and Commitment-Based Therapy on the Immune Function and Activity Limitations in Patients With Irritable Bowel Syndrome

2021 ◽  
Vol 31 (4) ◽  
pp. 271-279
Author(s):  
Sepideh Shakernejad ◽  
◽  
Javad Khalatbari ◽  
Majid-Mahmoud Alilou ◽  
◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Immune Function ◽  
Intervention Group ◽  
Control Group ◽  
Activity Limitations ◽  
Acceptance And Commitment ◽  
Before And After ◽  
Post Test ◽  
The Mean ◽  
Irritable Bowel

Introduction: Irritable bowel syndrome is the most common, costly, and disabling dysfunction of the gastrointestinal tract. Mental disorders can be one of the main factors in the onset, continuation, or exacerbation of gastrointestinal signs and symptoms in people with this syndrome. Commitment and acceptance therapy is a mixture of four approaches of awareness, acceptance, commitment, and behavior change, and its overall goal is to achieve psychological flexibility to move towards thought-based behavior. This treatment focuses less on reducing symptoms and more on improving the quality of life. Objective: This study aimed to determine the effectiveness of acceptance and commitment-based therapy on the immune function and activity limitations in patients with irritable bowel syndrome. Materials and Methods: This study was a quasi-experimental research with a pre-test, post-test design and a control group. Thirty patients with irritable bowel syndrome were randomly selected from those referred to a hospital clinic in Tabriz City, Iran. They were randomly divided into the intervention and control groups (15 in each group). The intervention group received acceptance and commitment group therapy for 8 sessions, while the control group did not receive any intervention. Both groups were assessed before and after the intervention, and in the follow-up phase using the activity limitations subscale of quality of life questionnaires (to measure activity limitations) and stool calprotectin test to assess safety performance. Data analysis was performed using descriptive statistics indices (mean and standard deviation) and analysis of variance with repeated measures, Bonferroni test, and analysis of covariance to test the study hypotheses. Results: The Mean±SD age of the intervention group was 34.53±18.38 years, and the Mean±SD age of the control group was 42.80±17.97 years. The significance levels of Levene’s and the Shapiro-Wilk test for all variables were greater than 0.05. Based on the results, the Mean±SD score of the activity limitations variable in the intervention group was 7.53±4.24 in the pre-test, 17.66±3.41 in the post test, and 17.26±3.65 in the follow-up. According to the results, activity limitations (P=0.027) and safety performance (P=0.034) were significantly different before and after the intervention. Conclusion: The present study’s findings show that acceptance and commitment-based therapy can play an influential role in improving patients’ immune function and promoting their activity limitations. Therefore, this treatment is recommended as a complementary therapy in patients with irritable bowel syndrome.

scholarly journals Efficacy and safety of Lactobacillus paracasei CNCM I-1572 and fructo- oligosaccharides in the treatment of patients with irritable bowel syndrome with constipation

2021 ◽  
Vol 1 (6) ◽  
pp. 57-62
Author(s):  
I. B. Khlinov ◽  
R. I. Khlynova ◽  
E. I. Voronova ◽  
E. V. Garanina ◽  
I. A. Gurikova ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Clinical Remission ◽  
Controlled Trial ◽  
Main Group ◽  
Lactobacillus Paracasei ◽  
Control Group ◽  
Treatment Regimens ◽  
Before And After ◽  
Mebeverine Hydrochloride ◽  
Irritable Bowel

The aim is to study the effect and safety of using the antispasmodic and synbiotic (Lactobacillus paracasei CNCM I-1572 in combination with fructooligosaccharides) in patients with irritable bowel syndrome with constipation.Materials and methods — prospective randomized controlled trial of 80 patients with irritable bowel syndrome with constipation. Patients in the main group (40 people) took mebeverine hydrochloride 200 mg 2 times a day and synbiotic (5x109 CFU Lactobacillus paracasei CNCM I-1572 and 5.2 g fructooligosaccharides) during 28 days. Patients in the control group (40 people) received mebeverine hydrochloride 200 mg 2 times a day during 28 days. Before and after treatment, patients underwent the GSPS questionnaire.Results — in control group clinical remission was achieved in 52.6% of patients. In the main group clinical remission was established in 92.3%, the increase was 39.7% (p <0.01). The relative risk of clinical remission when synbiotic included in the treatment for patients with irritable bowel syndrome with constipation is 1.75 (95% CI 1.28–2.4; p <0.01). When analyzing adverse events of the compared treatment regimens, no statistically significant differences were found (p = 0.75).Conclusion — the results of study demonstrate a significant increase in the effectiveness of therapy in patients with irritable bowel syndrome with constipation with the combined use of antispasmodic and synbiotic.

scholarly journals Blastocystis sp. Carriage and Irritable Bowel Syndrome: Is the Association Already Established?

Biology ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 340
Author(s):  
Fernando Salvador ◽  
Beatriz Lobo ◽  
Lidia Goterris ◽  
Carmen Alonso-Cotoner ◽  
Javier Santos ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Microscopic Examination ◽  
Parasitic Infection ◽  
Diagnostic Technique ◽  
Control Group ◽  
Cross Sectional ◽  
Significant Difference ◽  
Blastocystis Sp ◽  
Irritable Bowel ◽  
Asymptomatic Subjects

Background: The aim of the present study is to describe the occurrence of Blastocystis sp. detection among asymptomatic subjects and patients with irritable bowel syndrome in order to evaluate the potential association between irritable bowel syndrome and the parasitic infection. Methods: Cross-sectional study where adult patients with irritable bowel syndrome diagnosed according to Rome IV criteria were included. A control group was formed by asymptomatic subjects older than 18 years. Exclusion criteria were: immunosuppressive condition or having received any drug with demonstrated activity against Blastocystis sp. within the last 6 months before study inclusion. Epidemiological and clinical information was collected from all included participants. Two stool samples were obtained from all participants: one sample for microscopic examination and one sample for Blastocystis sp. PCR detection. Blastocystis sp. infection was defined by the positivity of any of the diagnostic techniques. Results: Seventy-two participants were included (36 asymptomatic subjects and 36 patients with irritable bowel syndrome). Thirty-five (48.6%) were men, and median age of participants was 34 (IQR 29–49) years. The overall rate of Blastocystis sp. carriage was 27.8% (20/72). The prevalence assessed through microscopic examination was 22.2% (16/72), while the prevalence measured by PCR was 15.3% (11/72). When comparing the presence of Blastocystis sp. between asymptomatic subjects and IBS patients, we did not find any statistically significant difference (36.1% vs. 19.4% respectively, p = 0.114). Conclusions: regarding the occurrence of Blastocystis sp., no differences were found between asymptomatic participants and patients with irritable bowel disease irrespective of the diagnostic technique performed.

scholarly journals Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
L. Quénéhervé ◽  
D. Drui ◽  
J. Blin ◽  
M. Péré ◽  
E. Coron ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Adrenal Insufficiency ◽  
Gastrointestinal Symptoms ◽  
Control Group ◽  
Non Profit ◽  
Acute Adrenal Insufficiency ◽  
Irritable Bowel ◽  
Rome Iv

AbstractGastrointestinal symptoms are frequent in acute adrenal insufficiency. Although digestive symptoms can significantly reduce quality of life, they are rarely described in patients with treated chronic adrenal insufficiency (CAI). We aimed to characterize digestive symptoms in CAI patients. We used the section pertaining functional bowel disorders of the Rome IV questionnaire. A questionnaire was published on the website of the non-profit patient association “Adrenals” (NPPA of CAI patients) for five months. Information on demographics, characteristics of adrenal insufficiency, digestive symptoms and quality of life was collected. The relatives of CAI patients served as a control group. We analyzed responses of 33 control subjects and 119 patients (68 primary adrenal insufficiency (PAI), 30 secondary adrenal insufficiency (SAI) and 21 congenital adrenal hyperplasia (CAH)). Abdominal pain at least once a week over the past 3 months was reported by 40%, 47% and 33% of patients with PAI, SAI and CAH respectively versus 15% for the controls (p = 0.01). Symptoms were consistent with the Rome IV criteria for irritable bowel syndrome in 27%, 33% and 33% of patients respectively versus 6% for the controls (p < 0.0001). Quality of life was described as poor or very poor in 35%, 57% and 24% of patients respectively versus 5% for the controls (p < 0.0001). In conclusion, digestive symptoms are frequent and incapacitating in CAI patients and similar to symptoms of irritable bowel syndrome in 30% of CAI patients. Assessment and management of digestive symptoms should be considered a priority for physicians treating patients with CAI.

scholarly journals Audio-guided self-hypnosis for reduction of claustrophobia during MR imaging: results of an observational 2-group study

2021 ◽  
Author(s):  
Adriane E. Napp ◽  
Torsten Diekhoff ◽  
Olf Stoiber ◽  
Judith Enders ◽  
Gerd Diederichs ◽  
...  
Keyword(s):  
High Risk ◽  
Mr Imaging ◽  
Odds Ratio ◽  
Control Group ◽  
Waiting Room ◽  
High Risk Patients ◽  
Imaging Results ◽  
Before And After ◽  
Risk Patients ◽  
And Coping

Abstract Objectives To evaluate the influence of audio-guided self-hypnosis on claustrophobia in a high-risk cohort undergoing magnetic resonance (MR) imaging. Methods In this prospective observational 2-group study, 55 patients (69% female, mean age 53.6 ± 13.9) used self-hypnosis directly before imaging. Claustrophobia included premature termination, sedation, and coping actions. The claustrophobia questionnaire (CLQ) was completed before self-hypnosis and after MR imaging. Results were compared to a control cohort of 89 patients examined on the same open MR scanner using logistic regression for multivariate analysis. Furthermore, patients were asked about their preferences for future imaging. Results There was significantly fewer claustrophobia in the self-hypnosis group (16%; 9/55), compared with the control group (43%; 38/89; odds ratio .14; p = .001). Self-hypnosis patients also needed less sedation (2% vs 16%; 1/55 vs 14/89; odds ratio .1; p = .008) and non-sedation coping actions (13% vs 28%; 7/55 vs 25/89; odds ratio .3; p = .02). Self-hypnosis did not influence the CLQ results measured before and after MR imaging (p = .79). Self-hypnosis reduced the frequency of claustrophobia in the subgroup of patients above an established CLQ cut-off of .33 from 47% (37/78) to 18% (9/49; p = .002). In the subgroup below the CLQ cut-off of 0.33, there were no significant differences (0% vs 9%, 0/6 vs 1/11; p = 1.0). Most patients (67%; 35/52) preferred self-hypnosis for future MR examinations. Conclusions Self-hypnosis reduced claustrophobia in high-risk patients undergoing imaging in an open MR scanner and might reduce the need for sedation and non-sedation coping actions. Key Points • Forty percent of the patients at high risk for claustrophobia may also experience a claustrophobic event in an open MR scanner. • Self-hypnosis while listening to an audio in the waiting room before the examination may reduce claustrophobic events in over 50% of patients with high risk for claustrophobia. • Self-hypnosis may also reduce the need for sedation and other time-consuming non-sedation coping actions and is preferred by high-risk patients for future examinations.

Sign in / Sign up

Export Citation Format

Share Document